Latest news with #AlignTechnology
Yahoo
a day ago
- Business
- Yahoo
Bear of the Day: Align Technology (ALGN)
Align Technology (ALGN), maker of the clear "smile straightener" Invisalign, reported Q2 2025 adjusted earnings per share (EPS) of $2.49, up 3.3% from the year-ago level. But the profit figure missed the Zacks Consensus Estimate by 3.1%.GAAP EPS for the quarter was $1.72, reflecting a rise of 43.4% from $1.28 in the comparable period of top line also missed expectations by 4.6%, decreasing 1.6% year-over-year to $1.01 the earnings announcement on July 30, ALGN shares imploded 36.6% the next can find more details on Align Segments and Margins in this article from July Stock Falls on Q2 Earnings and Revenue Miss, Margins DownBased on the company results, analysts have knocked down full-year EPS estimates from $10.33 to $10.10, representing 8.25% annual profit the 2025 topline estimate falls to $4 billion for roughly zero Repurchase Plan and New Insider MovesDuring the reported quarter, the company repurchased approximately 585.1 thousand shares of common stock at an average price of $164.14 per share, completing the $225.0 million open market repurchase initiated in the first quarter of 2025. This marked the completion of the $1.0 billion stock repurchase program, approved in January 2023, in its April 2025, its board of directors authorized a plan to repurchase up to $1.0 billion of common stock, expected to be completed over a period of up to three both the company and the CEO took advantage of the stock drop to accumulate more August 1, Align announced in a press release that President and CEO Joe Hogan stepped into the market and "Personally Purchases $1 Million of Align's Common Stock."Details of the transaction reveal that Hogan purchased 7,576 shares of Common Stock on August 1, 2025, at a price of $131.4851 per share, totaling $996,131. Following this transaction, Hogan directly owns 184,945 on August 8, Align announced a $200 Million Open Market Repurchase of common Take on ALGNI have been an investor in ALGN for many years because I thought very highly of two aspects of their business model:(1) Digital services that could economically and efficiently serve remote and poor communities at scale(2) Aggressive growth push into China and India where many tens of millions of kids need their servicesBut I have avoided the stock for several quarters now because of uncertainties. Now, with the current de-risking and a 2.5X price-to-sales multiple, I may be taking a closer look as we get more visibility about the growth model in the coming weeks and I dive into company presentation then, here is the Zacks Research Technology exited the second quarter of 2025 with weaker-than-expected results, wherein both earnings and revenues missed the Zacks Consensus Estimate. Also, revenues deteriorated on a year-over-year basis due to a decline in the Clear Aligner segment's sales. Contraction of both the gross and operating margins is a matter of a positive note, Clear Aligner volume grew in APAC and EMEA regions, driven by increased utilization across both orthodontists and general practitioners (GP) dentist channels, with strength in the adult segment. Additionally, ALGN's Imaging Systems & CAD/CAM Services business segment reported strong growth on a year-over-year basis, primarily due to iTero Lumina wand upgrades and increased services as more doctors transition to iTero Element 5D the quarter, Align Technology achieved a record number of teen cases, with over 6 million teens and kids having been treated with the Invisalign system globally and over 20 million total line: The downward estimates revisions were not that bad, so a buying opportunity is close at hand. The Zacks Rank will let you know. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Align Technology, Inc. (ALGN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Business Wire
2 days ago
- Business
- Business Wire
INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Align Technology, Inc. and Encourages Investors and Potential Witnesses to Contact Law Firm
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Align Technology, Inc. (NASDAQ: ALGN) focused on whether Align Technology and certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Align Technology investigation or if you are an Align Technology investor who suffered a loss and would like to learn more, you can provide your information here: You can also contact attorneys J.C. Sanchez or of Robbins Geller by calling 800/449-4900 or via e-mail at info@ THE COMPANY: Align Technology is a global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry. THE REVELATION: On July 31, 2025, Align Technology released second quarter 2025 financial results, disclosing revenue of $1.01 billion, representing a year-over-year decrease of 1.6%. Align Technology further revealed that it 'expect[s] to take a series of actions in the second half of fiscal 2025 to streamline operations and reallocate resources to better align with our long-term growth and profitability objective.' On this news, the price of Align Technology stock fell 37%. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Yahoo
4 days ago
- Business
- Yahoo
Jim Cramer Breaks Down the Selloff in Align Technology Stock
Align Technology, Inc. (NASDAQ:ALGN) is one of the stocks that Jim Cramer spoke about. Cramer highlighted that the company 'missed its numbers badly.' He remarked: 'What do you make of the shocking decline in a company like Align Technology? That's the maker of Invisalign clear aligners. It's the gold standard, the one that dentists love to recommend, but it missed its numbers badly, and its stock collapsed, down nearly 37%, one session. Let me tell you what CEO Joe Hogan, who again is no slouch, gave as his excuse for the weakness in his conference call. Listen to this, 'In the face of a challenging and uncertain macroeconomic backdrop characterized by global tariff volatility, ongoing inflation, elevated interest rates, and unstable consumer confidence, we're navigating with a clear focus to control what we can.' Then he says, 'significant headwinds across the consumer discretionary spend landscape' has come to hurt these guys. I say, well, wait, wait a second, wait a second. We're talking about clear braces here; we're talking about your teeth. To me, that's not really that much of a discretionary item, at least not in America, maybe in Britain. But most Americans get their teeth straightened, or at least they did. I mean, apparently now it's becoming discretionary spending. People must really be strapped. Because I believe Hogan, I've had him on the show a bunch of times.' A laptop and a computer monitor display a detailed stock market technical analysis chart. Photo by Jakub Zerdzicki on Pexels Align Technology (NASDAQ:ALGN) develops and markets Invisalign clear aligners, retainers, and iTero intraoral scanners, as it provides digital solutions for orthodontic and restorative dental treatments. The company's products include aligner systems for all age groups, 3D printed devices, and CAD/CAM software for dental professionals. While we acknowledge the potential of ALGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
4 days ago
- Business
- Business Wire
Align Technology Announces $200 Million Open Market Repurchase
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it is planning to repurchase $200 million of Align's common stock through open market repurchases under Align's $1.0 billion stock repurchase program that was approved by Align's Board of Directors in April 2025. 'We are pleased to announce our intention to repurchase $200 million of our common stock through open market transactions. This decision reflects the continued confidence of management and the Board in our long-term strategy and market opportunity and underscores the strength of our balance sheet and strong cash flow generation,' said John Morici, Align CFO and executive vice president, global finance. 'Align remains focused on executing its strategic plan, delivering superior outcomes for doctors and patients, and enhancing stockholder value by delivering sustainable growth and performance. In the face of a challenging and uncertain macroeconomic backdrop, we are navigating with a clear focus to control what we can and to continue to invest with discipline in the areas that will define our future.' The open market repurchases of Align's common stock will be executed pursuant to a Rule 10b5-1 trading plan. The timing and number of shares repurchased will be based on an evaluation of market conditions and other factors, including stock price, trading volume, general business and market conditions, and capital availability. The repurchases are expected to be completed by January 2026 and will be funded with Align's cash on hand. As of June 30, 2025, Align had approximately 72.5 million shares outstanding and $901,157 million in cash and cash equivalents. About Align Technology, Inc. Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 286.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc. Forward-Looking Statements This news release contains forward-looking statements, including statements regarding the expected completion date and form of the open market repurchases, the aggregate value of common stock to be repurchased under the repurchase program, our expectation that we will finance the repurchases with cash on hand, our confidence in our long-term strategy and market opportunity, our ability to execute on our strategic plan, deliver superior outcomes to doctors and patients and enhance stockholder value by delivering sustainable growth and performance, that the repurchases will provide value to our stockholders, our belief that we will continue to invest with discipline in areas that will define our future, as well as other statements regarding the planned open market repurchases under the repurchase program. Forward-looking statements contained in this news release relating to expectations about future events or results are based upon information available to Align as of the date hereof. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. As a result, actual results may differ materially and adversely from those expressed in any forward-looking statement. The foregoing and other risks are detailed from time to time in our periodic reports filed with the Securities and Exchange Commission ("SEC"), including, but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on February 28, 2025 and our latest Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which was filed with the SEC on May 8, 2025. Align undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Yahoo
6 days ago
- Business
- Yahoo
Henry Schein (HSIC) Reports Earnings Tomorrow: What To Expect
Dental and medical products company Henry Schein (NASDAQ:HSIC) will be reporting results this Tuesday morning. Here's what investors should know. Henry Schein missed analysts' revenue expectations by 2% last quarter, reporting revenues of $3.17 billion, flat year on year. It was a slower quarter for the company, with a miss of analysts' organic revenue estimates. Is Henry Schein a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Henry Schein's revenue to grow 2.9% year on year to $3.23 billion, improving from the 1.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.19 per share. Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 4 downward revisions over the last 30 days (we track 12 analysts). Looking at Henry Schein's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Envista delivered year-on-year revenue growth of 7.7%, beating analysts' expectations by 7%, and Align Technology reported a revenue decline of 1.6%, falling short of estimates by 4.8%. Envista traded up 10.1% following the results while Align Technology was down 36.8%. Read our full analysis of Envista's results here and Align Technology's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Henry Schein is down 7.4% during the same time and is heading into earnings with an average analyst price target of $75.85 (compared to the current share price of $67.98). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
